Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2020

View Archived Issues

Turning flexibility into toxicity

Taking the STING out of nuclear DNA

Taisho details antidepressant potential of V1b receptor antagonist THY-1773

Efflux pump furthers antibiotic resistance, but via unexpected mechanism

Polycomb protein EED inhibitors discovered at Shanghai Blueray Biopharma

XuanZhu Pharma identifies new ketohexokinase inhibitors

New STING receptor agonists identified at HitGen

Medshine Discovery patents c-Met inhibitors

Betta Pharmaceuticals identifies new SHP-2 inhibitors

Alkermes initiates phase II ARTISTRY-3 study of ALKS-4230

First patient dosed in phase I/II study of 4D-125

Trefoil Therapeutics initiates first clinical trial of TTHX-1114

Shionogi describes identification of clinical candidate P2X3 receptor antagonist S-600918

BioMarin receives complete response letter from FDA for valoctocogene roxaparvovec

Novel 3C-like protease inhibitors show efficacy in MERS-CoV-infected mice

Early interim data and regulatory update for phase II TRIDENT-1 study of repotrectinib

Enrollment ongoing in phase I study of ZF-874

Novartis initiates phase II study of LRX-712 in patients with knee osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...